CN105979943A - 肌营养不良的治疗方法 - Google Patents

肌营养不良的治疗方法 Download PDF

Info

Publication number
CN105979943A
CN105979943A CN201480070003.0A CN201480070003A CN105979943A CN 105979943 A CN105979943 A CN 105979943A CN 201480070003 A CN201480070003 A CN 201480070003A CN 105979943 A CN105979943 A CN 105979943A
Authority
CN
China
Prior art keywords
compound
subject
pharmaceutically acceptable
acceptable salt
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480070003.0A
Other languages
English (en)
Chinese (zh)
Inventor
厄恩斯特.D.布什
弗朗索瓦.尼克
凯瑟琳.贾格尔施米特
弗洛伦斯.S.纳穆
罗兰.布兰克
让-迈克尔.勒弗朗索瓦
克里斯托夫.佩肖托
皮埃尔.德普雷
尼古拉斯.特里巴利奥
皮特.T.B.P.威格林克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN105979943A publication Critical patent/CN105979943A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201480070003.0A 2013-10-25 2014-10-24 肌营养不良的治疗方法 Pending CN105979943A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361895832P 2013-10-25 2013-10-25
US61/895,832 2013-10-25
PCT/US2014/062178 WO2015061685A1 (en) 2013-10-25 2014-10-24 Methods for treatment of muscular dystrophies

Publications (1)

Publication Number Publication Date
CN105979943A true CN105979943A (zh) 2016-09-28

Family

ID=52993619

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480070003.0A Pending CN105979943A (zh) 2013-10-25 2014-10-24 肌营养不良的治疗方法

Country Status (9)

Country Link
US (2) US20160250188A1 (enExample)
EP (1) EP3060206A4 (enExample)
JP (1) JP2016538269A (enExample)
CN (1) CN105979943A (enExample)
AU (1) AU2014339917A1 (enExample)
BR (1) BR112016009214A8 (enExample)
CA (1) CA2928235A1 (enExample)
MX (1) MX2016005287A (enExample)
WO (1) WO2015061685A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110869044A (zh) * 2017-02-22 2020-03-06 倍奥英赛普特有限责任公司 肽和用肽治疗营养不良相关病症的方法
CN113924085A (zh) * 2019-04-12 2022-01-11 加利福尼亚大学董事会 用于增加肌肉量和氧化代谢的组合物和方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643856B1 (es) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
WO2019236677A1 (en) * 2018-06-05 2019-12-12 The Regents Of The University Of California Methods for treating muscular dystrophies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100168072A1 (en) * 2007-08-03 2010-07-01 Biomarin Iga Limited Drug Combinations for the Treatment of Duchenne Muscular Dystrophy
CN102149687A (zh) * 2008-09-11 2011-08-10 加拉帕戈斯股份有限公司 作为雄激素受体调节剂的新的咪唑烷化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITBO20090078A1 (it) * 2009-02-13 2010-08-14 Consiglio Nazionale Ricerche Composti per il trattamento del tumore alla prostata e procedimenti per la loro sintesi

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100168072A1 (en) * 2007-08-03 2010-07-01 Biomarin Iga Limited Drug Combinations for the Treatment of Duchenne Muscular Dystrophy
CN102149687A (zh) * 2008-09-11 2011-08-10 加拉帕戈斯股份有限公司 作为雄激素受体调节剂的新的咪唑烷化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANNA COZZOLI ET AL.: "GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy", 《PHARMACOLOGICAL RESEARCH》 *
FRANÇOIS NIQUE ET AL.: "Identification of a 4‑(Hydroxymethyl)diarylhydantoin as a Selective Androgen Receptor Modulator", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
GALAPAGOS NV: "NCT01397370, Multiple Ascending Dose Study of GLPG0492 in Healthy Subjects", 《CLINICALTRIALS.GOV, HTTPS://CLINICALTRIALS.GOV/CT2/SHOW/STUDY/NCT01397370?TERM=NCT01397370&RANK=1》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110869044A (zh) * 2017-02-22 2020-03-06 倍奥英赛普特有限责任公司 肽和用肽治疗营养不良相关病症的方法
CN113924085A (zh) * 2019-04-12 2022-01-11 加利福尼亚大学董事会 用于增加肌肉量和氧化代谢的组合物和方法
US12441716B2 (en) 2019-04-12 2025-10-14 The Regents Of The University Of California Compositions and methods for increasing muscle mass and oxidative metabolism

Also Published As

Publication number Publication date
WO2015061685A1 (en) 2015-04-30
US20190167640A1 (en) 2019-06-06
US20160250188A1 (en) 2016-09-01
AU2014339917A1 (en) 2016-05-12
EP3060206A1 (en) 2016-08-31
MX2016005287A (es) 2017-02-22
CA2928235A1 (en) 2015-04-30
JP2016538269A (ja) 2016-12-08
EP3060206A4 (en) 2017-04-19
BR112016009214A8 (pt) 2020-03-24

Similar Documents

Publication Publication Date Title
CN114929209A (zh) 肌萎缩侧索硬化的治疗
US20240058353A1 (en) Methods for treating gi tract disorders
EP3687577A1 (en) Combination therapies for treating muscular dystrophy
US20190167640A1 (en) Methods for treatment of muscular dystrophies
WO2015127556A1 (en) Methods and uses for inducing or facilitating defecation in a patient in need thereof
ES2762243T3 (es) Tratamiento de distrofia muscular
US11834445B2 (en) Polymorphic forms of metopimazine
Arora Duchenne muscular dystrophy: Still an incurable disease
Lee The dystrophinopathies
US9844554B2 (en) Prodrugs of metopimazine
JP2018509395A (ja) 筋肉の疾患および障害を治療するための方法および組成物
EP3585420A2 (en) Peptides and methods of treating dystrophy-related disorders using the same
Giourmas et al. β-Hydroxy-β-methylbutyrate enhances fast-twitch muscle and mitochondrial function, histopathology and mTORC1 signalling in the mdx dystrophic mouse
US20240100069A1 (en) Methods and Compositions for Treating Amyotrophic Lateral Sclerosis
Goemans et al. Therapy development and clinical outcome measures for Duchenne muscular dystrophy
HK40081935A (en) Treatment of amyotrophic lateral sclerosis
Maricelli Phenotypic Characterization and Treatment of a Novel Mouse Model for Limb-Girdle Muscular Dystrophy 2i

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160928

WD01 Invention patent application deemed withdrawn after publication